SG11202005799XA - DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS - Google Patents
DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORSInfo
- Publication number
- SG11202005799XA SG11202005799XA SG11202005799XA SG11202005799XA SG11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA
- Authority
- SG
- Singapore
- Prior art keywords
- fused ring
- ring compounds
- diaryl substituted
- c5ar inhibitors
- c5ar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609844P | 2017-12-22 | 2017-12-22 | |
| PCT/US2018/066677 WO2019126431A1 (en) | 2017-12-22 | 2018-12-20 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005799XA true SG11202005799XA (en) | 2020-07-29 |
Family
ID=66950014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005799XA SG11202005799XA (en) | 2017-12-22 | 2018-12-20 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10759807B2 (en) |
| EP (1) | EP3728202A4 (en) |
| JP (1) | JP7253557B2 (en) |
| KR (1) | KR102852027B1 (en) |
| CN (1) | CN111788184B (en) |
| AU (1) | AU2018388657C1 (en) |
| BR (1) | BR112020012374A2 (en) |
| CA (1) | CA3086111A1 (en) |
| IL (1) | IL275516B2 (en) |
| MA (1) | MA51327A (en) |
| MX (1) | MX2020006460A (en) |
| SG (1) | SG11202005799XA (en) |
| TW (1) | TWI817968B (en) |
| WO (1) | WO2019126431A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3630775B1 (en) | 2017-05-31 | 2022-12-14 | ChemoCentryx, Inc. | 6-5 FUSED RINGS AS C5a INHIBITORS |
| WO2018222601A1 (en) | 2017-05-31 | 2018-12-06 | Chemocentryx, Inc. | 5-5 FUSED RINGS AS C5a INHIBITORS |
| CN111406051A (en) | 2017-09-03 | 2020-07-10 | 安吉昂生物医药公司 | Vinylheterocycles as RHO-associated coiled coil kinase (ROCK) inhibitors |
| US10759807B2 (en) | 2017-12-22 | 2020-09-01 | Chemocentryx, Inc. | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors |
| EP3728203B1 (en) | 2017-12-22 | 2024-03-13 | ChemoCentryx, Inc. | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| ES2993034T3 (en) | 2018-04-02 | 2024-12-20 | Chemocentryx Inc | Prodrugs of fused-bicyclic c5ar antagonists |
| KR20230031981A (en) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | Methods and compositions for preventing type 1 diabetes |
| CN112300169B (en) * | 2019-07-26 | 2022-03-04 | 上海美迪西生物医药股份有限公司 | Pyrrolopyrazole derivatives, their preparation method and their application in medicine |
| EP4005638A4 (en) * | 2019-07-29 | 2023-07-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| MX2022006439A (en) | 2019-12-19 | 2022-07-19 | Active Biotech Ab | COMPOUNDS FOR THE TREATMENT OF EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARIZATION. |
| WO2021222971A1 (en) * | 2020-05-06 | 2021-11-11 | Dimerix Bioscience Ltd | Treatment for virus induced acute respiratory distress syndrome |
| EP4146191A1 (en) * | 2020-05-06 | 2023-03-15 | Dimerix Bioscience Pty Ltd | Treatment for acute respiratory distress syndrome |
| CA3175602A1 (en) * | 2020-05-07 | 2021-11-11 | Jerome Molette | Novel compounds for diagnosis |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
| US20220047592A1 (en) * | 2020-08-13 | 2022-02-17 | Chemocentryx, Inc. | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS |
| EP4237411A4 (en) | 2020-10-28 | 2024-08-14 | ChemoCentryx, Inc. | METHODS OF TREATMENT OF HIDRADENITIS SUPPURATUM |
| EP4262800A4 (en) * | 2020-12-21 | 2024-11-20 | ChemoCentryx, Inc. | TREATMENT OF C3 GLOMERULOPATHY USING A C5A INHIBITOR |
| KR102815351B1 (en) * | 2022-04-20 | 2025-05-29 | 국립목포대학교산학협력단 | Composition for preventing and treating valve calcification |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| DE60143041D1 (en) * | 2000-08-10 | 2010-10-21 | Pfizer Italia Srl | Bicyclic pyrazoles are effective as kinase inhibitors, processes for their preparation, and pharmaceutical compositions containing them |
| EP1322309B1 (en) | 2000-09-29 | 2008-08-13 | Neurogen Corporation | High affinity small molecule c5a receptor modulators |
| SE524438C2 (en) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Remote controlled door-related locking arrangement, first and second computer program products, carrying medium and a computer-soluble medium |
| US7902179B2 (en) | 2001-04-26 | 2011-03-08 | Ajinomoto Co., Inc. | Heterocyclic compounds |
| WO2003008829A1 (en) | 2001-07-19 | 2003-01-30 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Disengaging system having a parking blocking function for controlling a clutch |
| ITMI20012025A1 (en) | 2001-09-28 | 2003-03-28 | Dompe Spa | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINO ALKYLAMIDS OF R 2-ARY-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| EP1487798A4 (en) | 2002-03-28 | 2005-07-13 | Neurogen Corp | Substituted tetrahydroisoquinolines as c5a receptor modulators |
| AU2003225971A1 (en) | 2002-03-28 | 2003-10-13 | Yang Gao | Substituted biaryl amides as c5a receptor modulators |
| WO2003084524A1 (en) | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| EP1534680B1 (en) | 2002-08-14 | 2012-02-22 | Pharmaco Investments, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| WO2004018460A1 (en) | 2002-08-21 | 2004-03-04 | Neurogen Corporation | Amino methyl imidazoles as c5a receptor modulators |
| AU2003291403A1 (en) | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| WO2005007087A2 (en) * | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| GB0320020D0 (en) * | 2003-08-27 | 2003-10-01 | Mw Encap Ltd | Improved formulation for providing an enteric coating material |
| CN101318962A (en) * | 2003-09-17 | 2008-12-10 | 詹森药业有限公司 | Fused heterocyclic compound |
| WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| US20070112015A1 (en) | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| US20080119457A1 (en) * | 2006-08-24 | 2008-05-22 | Serenex, Inc. | Benzene, Pyridine, and Pyridazine Derivatives |
| EP2296475A4 (en) | 2008-06-20 | 2014-03-05 | Genentech Inc | Triazolopyridine jak inhibitor compounds and methods |
| LT3508477T (en) | 2008-12-22 | 2022-02-10 | Chemocentryx, Inc. | C5AR ANTAGONISTS |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| SI2585064T1 (en) | 2010-06-24 | 2017-08-31 | Chemocentryx, Inc. | C5ar antagonists |
| GB201016880D0 (en) * | 2010-10-07 | 2010-11-17 | Riotech Pharmaceuticals Ltd | Phosphodiesterase inhibitors |
| US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| AU2013302473B2 (en) * | 2012-08-16 | 2017-08-10 | Janssen Pharmaceutica Nv | Pyrrolopyrazoles as N-type calcium channel blockers |
| CN103421006B (en) | 2013-08-18 | 2016-06-22 | 上海师范大学 | 2,3,5,7-tetra-substituted dihydro pyrazol hexahydropyridine derivant and its preparation method and application |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| WO2017176620A2 (en) | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | SOLUBLE C5aR ANTAGONISTS |
| EP3630775B1 (en) | 2017-05-31 | 2022-12-14 | ChemoCentryx, Inc. | 6-5 FUSED RINGS AS C5a INHIBITORS |
| WO2018222601A1 (en) | 2017-05-31 | 2018-12-06 | Chemocentryx, Inc. | 5-5 FUSED RINGS AS C5a INHIBITORS |
| US10759807B2 (en) | 2017-12-22 | 2020-09-01 | Chemocentryx, Inc. | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors |
| EP3728203B1 (en) | 2017-12-22 | 2024-03-13 | ChemoCentryx, Inc. | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| ES2993034T3 (en) | 2018-04-02 | 2024-12-20 | Chemocentryx Inc | Prodrugs of fused-bicyclic c5ar antagonists |
-
2018
- 2018-12-20 US US16/226,898 patent/US10759807B2/en active Active
- 2018-12-20 CA CA3086111A patent/CA3086111A1/en active Pending
- 2018-12-20 SG SG11202005799XA patent/SG11202005799XA/en unknown
- 2018-12-20 KR KR1020207020946A patent/KR102852027B1/en active Active
- 2018-12-20 IL IL275516A patent/IL275516B2/en unknown
- 2018-12-20 EP EP18890087.2A patent/EP3728202A4/en active Pending
- 2018-12-20 JP JP2020534276A patent/JP7253557B2/en active Active
- 2018-12-20 WO PCT/US2018/066677 patent/WO2019126431A1/en not_active Ceased
- 2018-12-20 BR BR112020012374-9A patent/BR112020012374A2/en active Search and Examination
- 2018-12-20 AU AU2018388657A patent/AU2018388657C1/en active Active
- 2018-12-20 CN CN201880083298.3A patent/CN111788184B/en active Active
- 2018-12-20 MX MX2020006460A patent/MX2020006460A/en unknown
- 2018-12-20 MA MA051327A patent/MA51327A/en unknown
- 2018-12-21 TW TW107146418A patent/TWI817968B/en active
-
2020
- 2020-07-27 US US16/939,667 patent/US11485737B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI817968B (en) | 2023-10-11 |
| KR102852027B1 (en) | 2025-08-27 |
| JP2021506900A (en) | 2021-02-22 |
| EP3728202A4 (en) | 2021-05-26 |
| AU2018388657C1 (en) | 2023-03-23 |
| RU2020124094A (en) | 2022-01-24 |
| KR20200110656A (en) | 2020-09-24 |
| AU2018388657A1 (en) | 2020-07-09 |
| IL275516A (en) | 2020-08-31 |
| US11485737B2 (en) | 2022-11-01 |
| TW201934552A (en) | 2019-09-01 |
| AU2018388657B2 (en) | 2022-12-01 |
| WO2019126431A1 (en) | 2019-06-27 |
| CA3086111A1 (en) | 2019-06-27 |
| US20210009596A1 (en) | 2021-01-14 |
| BR112020012374A2 (en) | 2020-11-24 |
| IL275516B2 (en) | 2023-12-01 |
| NZ765590A (en) | 2024-01-26 |
| US20190194208A1 (en) | 2019-06-27 |
| CN111788184A (en) | 2020-10-16 |
| JP7253557B2 (en) | 2023-04-06 |
| MA51327A (en) | 2021-05-26 |
| CN111788184B (en) | 2023-12-22 |
| IL275516B1 (en) | 2023-08-01 |
| MX2020006460A (en) | 2020-11-06 |
| EP3728202A1 (en) | 2020-10-28 |
| US10759807B2 (en) | 2020-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275516A (en) | Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors | |
| IL275500A (en) | Diaryl substituted 6,5-fused ring compounds as c5ar inhibitors | |
| SG11202104326TA (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| IL264092A (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| WO2016044463A3 (en) | Mk2 inhibitors and uses thereof | |
| SG11202000532SA (en) | Compounds, compositions and methods | |
| ZA201700737B (en) | Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer | |
| PL3676297T3 (en) | Compounds, compositions and methods | |
| SI3397631T1 (en) | Substituted 3-azabicyclo(3.1.0)hexanes as ketohexokinase inhibitors | |
| EP3160940A4 (en) | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds | |
| IL271399A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| IL251775B (en) | Substituted 2, 4-diamino quinoline compounds, compositions comprising same and uses thereof | |
| IL270505B1 (en) | Compounds, compositions and methods | |
| IL278262A (en) | Oxo-substituted compound | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| IL282905A (en) | Cycloalkane-1,3-diamine derivative | |
| IL259556A (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds | |
| PL3515454T3 (en) | Crystalline polymorphic form of 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinane | |
| PL3589637T3 (en) | Compounds useful for inhibiting ror-gamma-t | |
| HK40040511A (en) | Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors | |
| MX2016017019A (en) | Method for preparation of 4-alkoxy-1,1,1-trifluorobut-3-en-2- ones from 1,1,1-trifluoroacetone. | |
| WO2016040313A3 (en) | Methods of treating cancer comprising administering a ppar-gamma agonist | |
| PL3589638T3 (en) | Compounds useful for inhibiting ror-gamma-t | |
| GB201714439D0 (en) | Organic intermediate 1,6-cyclohexanedione synthesis method | |
| MY174415A (en) | Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof |